Vanda Pharmaceuticals, Inc. (VNDA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$5.25-1.50%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Warn: Primary pillar under pressure — Net loss improves toward -$49 million in Q1 2026: Q2 FY26 GAAP EPS -1.04 vs consensus -0.50 (miss).
Vanda raised 2026 revenue guidance to $240M-$290M. New product NEREUS drives growth. Net loss improved from -$141M to -$49M in Q1. FDA partnership supports faster drug reviews.
Vanda missed earnings in recent quarters. It still loses money. Revenue growth may slow. Management changes add uncertainty.
The market expects about 39% revenue growth. Our fair value is near $45. We see risk from ongoing losses and execution.
Breaks if: Net loss worsens beyond -$49M in Q1 2026
Breaks if: NEREUS fails to contribute meaningfully to revenue in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
VNDA represents a speculative growth investment. The company is currently in a watch state due to recent earnings misses and weak financial performance, which may impact its growth trajectory.
The market seems to price VNDA as relatively cheap compared to its peers. However, there is an expectations gap, indicating that the market anticipates further challenges ahead.
Management is focused on launching and growing its products, with some early sales reported from NEREUS™. However, the overall financial performance remains weak, and there is a high probability of missing earnings in the near term.
The future performance of VNDA hinges on the success of its product launches and the overall health of the healthcare sector. Key factors include guidance from management and performance of sector bellwethers.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss has put pressure on the thesis. Recent financial performance remains weak, which is concerning. The company reported a significant loss in Q2 2026, missing consensus estimates.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Commercially launch NEREUS™ and expand its market presence with direct-to-consumer platform and upcoming personal promotion.
Stated as a priority in 2 of last 2 quarters. NEREUS™ launched commercially in Q2 2026 with net product sales of $1.0 million reported in Q2 2026. Management expects personal promotion to start later in 2026. The trajectory shows initial commercial availability with early sales, delivering on launch but still early in growth phase.
“NEREUS™ launched commercially in Q2 2026 with direct-to-consumer offering via nereus.us; personal promotion expected later in 2026.”
“NEREUS™ launched via nereus.us, an innovative direct-to-consumer platform; personal promotion expected later in 2026.”
Breaks if: Revenue falls below $240M in FY26
Commercially launch NEREUS™ and expand its market presence with direct-to-consumer platform and upcoming personal promotion.
Stated as a priority in 2 of last 2 quarters. NEREUS™ launched commercially in Q2 2026 with net product sales of $1.0 million reported in Q2 2026. Management expects personal promotion to start later in 2026. The trajectory shows initial commercial availability with early sales, delivering on launch but still early in growth phase.
“NEREUS™ launched commercially in Q2 2026 with direct-to-consumer offering via nereus.us; personal promotion expected later in 2026.”
“NEREUS™ launched via nereus.us, an innovative direct-to-consumer platform; personal promotion expected later in 2026.”
In the next 1 to 3 years, VNDA's trajectory will depend heavily on its ability to execute on product launches and navigate sector challenges. Not investment advice.